Alkermes PLC (NAS:ALKS)
$ 29.02 -0.3 (-1.02%) Market Cap: 4.70 Bil Enterprise Value: 4.15 Bil PE Ratio: 14.88 PB Ratio: 3.63 GF Score: 71/100

Alkermes Plc at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 27, 2023 / 03:30PM GMT
Release Date Price: $26.55 (-1.42%)
Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Research Analyst

It's been around for a while, and I've admired for a long time. However, I only recently had an opportunity to pick up coverage of Alkermes, and I'm excited to do so. Frankly, I think that this is long been a neuro innovator that has been overlooked and it is becoming increasingly a more -- a company more focused on neuro innovation and developing a pipeline drugs -- pipeline of drugs meant to treat a range of neurological and psychiatric disorders. And in addition, it has a strong commercial base. So with me today is Blair Jackson, the company's Chief Operating Officer. Blair, welcome. Good to see you.

Blair C. Jackson
Alkermes plc - Executive VP & COO

Nice to see you as well.

Questions & Answers

Charles Cliff Duncan
Cantor Fitzgerald & Co., Research Division - Research Analyst

Thanks for joining. I think Blair we'll start probably with an overview and -- I like your socks, I'm a cyclist as well. And then we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot